title: Sporadic adult-onset hypophosphatemic osteomalacia caused by excessive action of fibroblast growth factor 23.
abstract: A 50-year-old man without family history of metabolic bone disease was referred to our hospital with a 5-year history of progressively worsening spinal and bilateral diffuse leg pain and proximal muscle weakness. Two years before admission, he was diagnosed as ankylosing spondylitis by a rheumatologist and was maintained on low-dose prednisone therapy without benefit. He developed progressive spinal and thoracic deformities, resulting in a 10 cm loss in height in the preceding 2 years. On physical examination, marked thoracic kyphosis and pectus carinatum was noted. Plain radiograph revealed pseudofracture in the right femoral neck. Laboratory findings showed a normal level of serum calcium, elevated level of serum alkaline phosphatase and inappropriately increased urinary phosphate excretion despite extreme hypophosphatemia. He was diagnosed as adult-onset hypophosphatemic osteomalacia caused by renal phosphate wasting. Serum fibroblast growth factor 23 was the upper limit of normal despite extreme hypophosphatemia and no neoplastic lesion potentially inducing hypophosphatemic osteomalacia could be identified in a thorough search including imaging studies of his entire body. Oral administration of phosphate and activated vitamin D together with dipyridamole relieved the persistent pain and weakness, and he became fully ambulatory.
authors.affiliation: Department of General Internal Medicine, Ohta-Nishinouchi Hospital, Koriyama. gim-hoshino@ohta-hp.or.jp
authors.forename: Chisho
authors.initials: C
authors.lastname: Hoshino
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Satoh
authors.forename: Shinichi
authors.initials: S
authors.lastname: Sugawara
authors.forename: Chizuko
authors.initials: C
authors.lastname: Kuriyama
authors.forename: Akio
authors.initials: A
authors.lastname: Kikuchi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ohta
mesh_terms: D017668:Age of Onset; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood* / Q000378:metabolism; D006801:Humans; D017674:Hypophosphatemia / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010018:Osteomalacia / Q000097:blood* / Q000209:etiology*; D010710:Phosphates / Q000097:blood*; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D010710:Phosphates; D010726:Phosphodiesterase Inhibitors; D014807:Vitamin D; D005346:Fibroblast Growth Factors; D004176:Dipyridamole; D000089703:Fibroblast Growth Factor-23